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Introduction: Thymic epithelial tumors are rare mediastinal malig-
nancies that can be invasive and difficult to treat. Insulin-like growth
factor-1 receptor (IGF-1R) is a transmembrane receptor implicated
in the regulation of cell metabolism, growth, and survival. As higher
levels of IGF-1R protein expression may be associated with relative
sensitivity to anti-IGF-1R antibody treatment, we investigated
IGF-1R expression in thymic malignancies.
Methods: Sixty-three thymic tumors (56 thymomas and seven
thymic carcinomas) were analyzed for total IGF-1R expression
using immunohistochemistry with a specific antibody (clone G11,
Roche-Ventana, Tucson, AZ). Expression levels were correlated
with relevant clinical and pathologic variables, including epidermal
growth factor receptor and KIT expression, and patient outcome.
Results: IGF-1R staining was negative in 13 (21%) cases, low (1) in
20 (32%) cases, moderate (2) in 20 (32%) cases, and high (3) in 10
(16%) cases. Moderate to high IGF-1R staining was observed in 6 of 7
(86%) thymic carcinomas and in 24 of 56 (43%) thymomas (p 
0.039). Moderate to high IGF-1R staining was associated with high
epidermal growth factor receptor staining (p  0.015). By multi-
variate analysis, only tumor stage and histologic type were signifi-
cant prognostic factors on time to progression (hazard ratio [HR] 
4.12, 95% confidence interval [CI]: 1.98–14.23; p  0.010 and
HR  2.79, 95% CI: 1.62–12.50; p  0.018, respectively). There
was no association between IGF-1R expression and time to progres-
sion (HR  3.07, 95% CI: 0.38–24.59; p  0.291).
Conclusion: A majority of thymic malignancies display moderate to
high expression of IGF-1R. The lack of preclinical models prevented
us to further study the functional consequences of anti-IGF-1R
therapy in this setting. However, given correlations in other cancers,
these data support the evaluation of anti-IGF-1R inhibitors in thymic
tumors.
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Thymic epithelial tumors are rare mediastinal malignanciesthat can be invasive and difficult to treat. This pathologic
classification distinguishes thymomas from thymic carcino-
mas. The former are further subdivided into types A, AB, B1,
B2, and B3,1 based on the morphology of epithelial cells
(with an increasing degree of atypia from type A to type B3),
the relative proportion of the nontumoral lymphocytic com-
ponent (decreasing from types B1 to B3), and resemblance to
the normal thymic architecture.1 For clinicians, the degree of
invasion or tumor stage is generally considered the most
important indicator of overall survival.2 As thymic tumors
tend to present with local and locoregional tumor growth,
surgical resection is the keystone of the treatment.3 However,
current therapeutic options are limited for unresectable, re-
current, or metastatic thymic tumors, because chemotherapy
produces modest response rates.3
Insulin-like growth factor-1 receptor (IGF-1R) is a
tyrosine kinase transmembrane receptor implicated in the
regulation of cell metabolism, growth, and survival.4 Many
epithelial tumors, including lung5 and breast6 cancers, show
altered expression of IGF-1R signaling pathway components.
Preclinical studies show that IGF-1R overexpression may
induce tumor formation and promote the development of
metastases.7,8 The IGF-1R signaling pathway has thus
emerged as a potential therapeutic target in various epithelial
cancers.9 Our group recently identified higher levels of
IGF-1R protein expression to be associated with relative
sensitivity to anti-IGF-1R antibody treatment in lung cancer
cell lines.10
In a previous comprehensive genomic study of a cohort
of 45 thymic epithelial tumors, we identified IGF-2 binding
protein-3 (IGF-2BP3), a protein that forms complexes with
circulating IGF-1 and regulates IGF-1R activation,11 to have
lower expression in thymomas versus thymic carcinomas.12
To further explore this finding, we analyzed the expression
levels of IGF-1R in a cohort of thymic tumors. We correlated
results with the expression levels of two other receptor
tyrosine kinases known to be expressed in thymic epithelial
tumors, namely the epidermal growth factor receptor (EGFR)
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and KIT. We also explored the value of IGF-1R expression as
a predictor of prolonged time to progression in resected
thymic malignancies.
PATIENTS AND METHODS
Tumor Tissue Specimens
Tumor tissue specimens from 63 patients with resected
thymoma or thymic carcinoma who underwent surgical re-
section at Memorial Sloan-Kettering Cancer Center from
January 1997 to December 2007 were obtained with patients’
consent under institutional tissue procurement protocols. Tu-
mor specimens for this study were selected based on tissue
availability in Memorial Sloan-Kettering Cancer Center tu-
mor banks. Formalin-fixed, paraffin-embedded tumor sam-
ples were reviewed by a reference pathologist (M.F.Z.) for
tumor histologic classification according to the 2004 World
Health Organization criteria.1 Tumor stage was determined
according to the Masaoka system.2 Given the retrospective
nature of the study, radiologic workup was not performed for
all patients at similar time intervals. However, all patients had
regular follow-up with systematic computed tomography
scans after initial treatment, usually every 6–12 months.
Construction of a Tissue Microarray
A tissue microarray was constructed using 45 of these
tumor specimens, using standard methods.13 Briefly, triplicate
0.6 mm biopsy cores were taken from selected areas contain-
ing a high ratio of tumor epithelial cells on parallel hematox-
ylin and eosin-stained sections and arrayed onto master par-
affin blocks using a manual tissue arrayer (Beecher
Instruments, Sun Prairie, WI). For the remaining 18 tumor
specimens, which were all resected after neoadjuvant treat-
ment, immunohistochemistry was done on individual paraf-
fin-embedded tumor blocks.
Immunohistochemistry
For immunohistochemistry, 5-m sections from the
tissue microarray or the tumor blocks were deparaffinized in
xylene and dehydrated in graded alcohols. Sections were
stained using a Ventana Symphony automated immunohisto-
chemical stainer (Ventana, Tucson, AZ) according to manu-
facturer’s guidelines. Immunostainings were performed with
an avidin-biotin detection system. Diaminobenzidine hydro-
chloride solution with hydrogen peroxide (Ventana Gen II,
DAB basic kit, Ventana) was the chromogen.
Total IGF-1R expression was measured using a rabbit
monoclonal anti-IGF-1R antibody clone G11 (1:1000) from
Roche (Ventana). IGF-1R expression levels at immunohisto-
chemistry with this antibody were recently demonstrated to
be highly correlated with IGF-1R mRNA levels at reverse
transcription-polymerase chain reaction.14 EGFR immunohis-
tochemistry was done using a mouse monoclonal anti-EGFR
antibody clone 31G7 (1:1000) from Invitrogen (Camarillo,
CA) and antigen retrieval by pepsin at 0.5%. KIT staining
was performed using a rabbit polyclonal anti-KIT antibody
(A4502; 1:2000) from Dako (Carpinteria, CA).
The staining intensity of the epithelial tumor cells was
qualitatively evaluated from 0 (no staining) to 1 (low
staining), 2 (moderate), and 3 (elevated staining) by two
investigators (N.G. and M.F.Z.), who were blinded to clinical
data. For EGFR and IGF-1R, only membrane staining of
epithelial cells was evaluated.10 For KIT, either cytoplasmic
or membrane staining was considered positive. Negative and
positive controls were included in all studies.
Statistical Methods
All patients were included in the statistical calculations.
Follow-up was obtained in all cases and was censored on
August 31, 2008. Categorical variables were compared using
the Fisher’s exact test. Survival calculations were assessed
using the Kaplan-Meier method.15 Relevant parameters were
studied for influence on time to progression (defined as the
time interval from the diagnosis to the first tumor recurrence)
by univariate and multivariate analysis using a stepwise Cox
proportional hazards method (entry and exit p  0.10).
Results were considered significant at the 0.05 level. Statis-
tical analyses were performed using the SPSS software pro-
gram (Chicago, IL), version 17.0.
RESULTS
Patient Demographics
The clinical characteristics of the 63 patients with
examined thymic tumors are listed in Table 1. In patients who
had tumor resected after neoadjuvant chemotherapy, patients
received cyclophosphamide-doxorubicin-cisplatin in 11
cases, cisplatin-etoposide in three cases, and cisplatin-etopo-
side-ifosfamide in one case. No patient received EGFR in-
hibitors before resection of the thymic tumor.
TABLE 1. Patients Demographics
Characteristics n
Total 63
Gender
Men 27
Women 36
Masaoka stage
I 24
II 17
III 17
IV 5
WHO type
A 5
AB 12
B1 8
B2 21
B3 10
Thymic carcinoma
Squamous cell carcinoma 7
Previous treatment
No 48
Yes 15
Girard et al. Journal of Thoracic Oncology • Volume 5, Number 9, September 2010
Copyright © 2010 by the International Association for the Study of Lung Cancer1440
EGFR and KIT Staining
Results of EGFR and KIT staining have been reported
elsewhere for 45 of the 63 tumors.12 EGFR staining was low
(1) in 14 (22%) cases, moderate (2) in 16 (25%) cases,
and high (3) in 32 (51%) cases (Table 2, Figures 1A and B).
Only one (2%) tumor did not express EGFR. High EGFR
expression was observed in six (86%) thymic carcinomas and
26 (46%) thymomas (p  0.057). Among thymomas, high
EGFR expression was associated with a higher tumor stage
(stages III–IV) (p  0.002). KIT was expressed in only four
(6%) tumors, including three thymic carcinomas and one
thymoma (p  0.003) (Table 2, Figure 1C). Staining was
negative in the remaining 59 (94%) cases.
IGF-1R Staining
IGF-1R expression was limited to epithelial tumor cells
with predominant membranous localization and weak cyto-
plasmic localization, as described in other series.10,14 IGF-1R
was not present in surrounding lymphocytic and stromal
cells. IGF-1R staining was negative in 13 (21%) cases, low
(1) in 20 (32%) cases, moderate (2) in 20 (32%) cases,
and high (3) in 10 (16%) cases (Table 2, Figure 2).
Moderate (2) to high (3) IGF-1R staining was observed in
six of seven (86%) thymic carcinomas and in 24 of 56 (43%)
thymomas (p  0.039).
IGF-1R levels in the tumors of three patients (patients
44, 53, and 63) were compared in tumor biopsies before and
after preoperative chemotherapy, and results were similar.
Among thymomas, a moderate to high IGF-1R expression
was associated with a high tumor stage (stages III–IV) (p 
0.007). No significant differences in IGF-1R expression lev-
els were observed between A versus B histologic types (p 
0.100). Moderate to high IGF-1R staining was associated
with high (3) EGFR staining (p  0.015 in the whole
cohort; p  0.034 in thymomas).
Outcome
Median follow-up was 60.9 months (range 16–208
months). At the time of analysis, all but eight patients were
alive, and 1-, 5-, and 10-year survival were 98%, 88%, and
TABLE 2. Results of Immunohistochemical Staining for
IGF-1R, EGFR, and KIT
Tumor Pretreated
Pathology Immunohistochemistry
Type Stage IGF1-R EGFR KIT
1 No A III 3 3 0
2 No A I 2 2 0
3 No A II 1 1 0
4 Yes A III 3 3 0
5 Yes A III 3 3 0
6 No AB I 0 1 0
7 No AB I 2 3 0
8 No AB II 3 2 3
9 No AB II 2 3 0
10 No AB I 0 1 0
11 No AB I 1 2 0
12 No AB I 2 3 0
13 No AB I 1 2 0
14 No AB I 1 1 0
15 No AB II 2 2 0
16 No AB II 0 3 0
17 No AB II 1 2 0
18 No B1 II 0 1 0
19 No B1 I 0 1 0
20 No B1 I 1 1 0
21 No B1 I 1 3 0
22 No B1 II 0 0 0
23 No B1 I 1 2 0
24 No B1 I 1 1 0
25 No B1 II 1 2 0
26 No B2 III 2 3 0
27 No B2 II 1 1 0
28 No B2 I 1 3 0
29 No B2 III 0 2 0
30 No B2 I 0 3 0
31 No B2 II 1 1 0
32 No B2 II 1 3 0
33 No B2 I 2 2 0
34 No B2 I 1 2 0
35 No B2 I 2 1 0
36 No B2 I 3 2 0
37 No B2 I 1 1 0
38 No B2 I 0 1 0
39 No B2 II 0 3 0
40 Yes B2 III 3 2 0
41 Yes B2 III 2 2 0
42 Yes B2 IV 2 3 0
43 Yes B2 III 2 3 0
44 Yes B2 III 2 2 0
45 Yes B2 III 2 3 0
46 Yes B2 III 2 3 0
47 No B3 I 2 3 0
48 No B3 I 0 3 0
49 No B3 II 0 1 0
50 No B3 II 3 3 0
51 No B3 II 2 3 0
52 Yes B3 IV 3 3 0
53 Yes B3 IV 1 3 0
54 Yes B3 IV 1 3 0
55 Yes B3 III 1 3 0
56 Yes B3 III 0 3 0
Tumor Pretreated
Pathology Immunohistochemistry
Type Stage IGF1-R EGFR KIT
57 No Thymic
carcinoma
I 2 3 0
58 No Thymic
carcinoma
III 2 3 0
59 No Thymic
carcinoma
III 1 3 0
60 No Thymic
carcinoma
IV 3 3 3
61 No Thymic
carcinoma
III 2 3 3
62 No Thymic
carcinoma
II 2 3 0
63 Yes Thymic
carcinoma
III 3 2 3
IGF1-R, insulin-like growth factor-1 receptor; EGFR, epidermal growth factor
receptor.
Journal of Thoracic Oncology • Volume 5, Number 9, September 2010 IGF-1R Expression in Thymic Malignancies
Copyright © 2010 by the International Association for the Study of Lung Cancer 1441
73%, respectively (Figure 3A). Eleven patients had experi-
enced tumor recurrence. One-, 5-, and 10-year time-to-pro-
gression rates were 97%, 69%, and 62%, respectively (Figure
3B). As patients with resected thymic tumor had a prolonged
survival, we used time to progression as a primary end point
to identify potential prognostic variables. Factors unfavorably
influencing time to progression at univariate analysis were the
following: stages III–IV (hazard ratio [HR]  12.32; 95%
confidence interval [CI]: 2.84–18.08; p  0.001; Figure 3C),
histologic type of thymic carcinoma (HR  6.35; 95% CI:
1.42–28.41; p  0.005; Figure 3D), administration of neoad-
juvant treatment (HR  7.67; 95% CI: 2.03–29.00; p 
0.001), and high EGFR expression (HR  2.10; 95% CI:
1.18–4.53; p  0.038), high KIT expression (HR  2.38;
95% CI: 1.44–3.94; p  0.001), and moderate to high
IGF-1R expression (HR  13.11; 95% CI: 1.68–26.62; p 
0.001) in the tumor tissue (Figure 3E). However, at multi-
variate analysis, only tumor stage and histologic type re-
FIGURE 1. Epidermal growth factor
receptor (EGFR) and KIT immunohis-
tochemical stainings: (A) moderate
EGFR staining in a type A thymoma;
(B) high EGFR staining in a thymic
carcinoma; and (C) high KIT staining
in another thymic carcinoma.
FIGURE 2. Insulin-like growth fac-
tor-1 receptor IGF-1R immunohisto-
chemical stainings: (A) low IGF-1R
staining in a type B2 thymoma; (B)
moderate staining in a type B3 thy-
moma; and (C) high staining in a
thymic carcinoma.
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FIGURE 3. A, Overall survival; and (B) time to progression curves for the 63 analyzed patients; (C) time to progression ac-
cording to tumor stage (HR  12.3; 95% CI: 2.8–18.1; p  0.001 at univariate analysis); (D) tumor histologic type (HR 
6.35; 95% CI: 0.32–0.62; p  0.005 at univariate analysis); and (E) level of IGF-1R expression in the tumor tissue (HR 
13.11; 95% CI: 1.68–26.62; p  0.001 at univariate analysis). HR, hazard ratio; CI, confidence interval; IGF-1R, insulin-like
growth factor-1 receptor.
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mained significant prognostic factors on time to progression
(HR 4.12; 95% CI: 1.98–14.23; p 0.010 and HR 2.79;
95% CI: 1.62–12.50; p  0.018, respectively) (Table 3).
There was no association between IGF-1R expression and
time to progression (HR  3.07; 95% CI: 0.38–24.59; p 
0.291).
DISCUSSION
The IGF-1R pathway represents a promising therapeu-
tic target in many human cancers. In thymic malignancies,
figitumumab (CP751,871; Pfizer, New York, NY), a mono-
clonal antibody against IGF-1R, recently showed clinical
activity in a patient with refractory thymoma.16 Therefore, we
investigated the expression of IGF-1R in a cohort of 56
thymomas and seven thymic carcinomas using immunohis-
tochemistry with a specific antibody. Our results indicate that
moderate to high IGF-1R expression was more frequent in
thymic carcinomas than in thymomas (86% versus 43%,
respectively, p  0.039).
IGF-1R was previously reported to be more frequently
overexpressed in squamous cell histology carcinoma tumors.
In non-small cell lung cancer (NSCLC), 70–80% of squa-
mous cell carcinoma tumors exhibit high IGF-1R expression
levels, when only 25–35% of adenocarcinoma tumors do
so.10,14,17 High IGF-1R expression has also been reported in
esophageal squamous cell carcinoma.18 In our study, all the
thymic carcinomas were of squamous cell histology. Even if
squamous cell carcinomas are less frequently well differen-
tiated (keratinizing) in the thymus than in other organs,19
these data suggest that the activation of the IGF-1R signaling
pathway might represent a hallmark of squamous cell carci-
noma histologic differentiation.
In the thymic malignancies examined here, IGF-1R
expression was significantly associated with EGFR overex-
pression (p  0.015). The association of concurrent high
levels of IGF-1R and EGFR expression has also been re-
ported in NSCLC.14,17,20 Recent data from in vitro models
suggest that IGF-1R may interact with EGFR through the
formation of heterodimers, leading to the concurrent
transphosphorylation of the 2 receptors,21 and the activation
of common downstream signaling pathways.22,23 Crosstalk
between EGFR and IGF-1R may also exist, as demonstrated
in breast cancer cell lines.24 EGFR/IGF-1R coexpression in
lung and breast cancer may reflect the existence of similar
regulation or coselection processes during cancer progres-
sion. In NSCLC and sarcoma cell lines sensitive to R1507
(Roche), a monoclonal antibody against IGF-1R, IGF-1R
phosphorylation was sufficient and required for AKT activa-
TABLE 3. Prognostic Factors Influencing Time to Progression
Variable
Univariate Analysis Multivariate Analysis
5-yr Survival (%) Hazard Ratio 95% CI p Hazard Ratio 95% CI p
Patient characteristics
Gender
Female 72 1 1
Male 63 2.12 0.62–7.25 0.164 1.07 0.30–3.85 0.915
Age
70-yr 95 1 1
70-yr 65 3.95 0.48–3.23 0.169 1.24 0.81–6.53 0.180
Tumor characteristics
Stage
I–II 100 1 1
III–IV 33 12.32 2.84–18.08 0.001 4.12 1.98–14.23 0.010
Histologic type
Thymoma 75 1 1
Thymic carcinoma 40 6.35 1.42–28.41 0.005 2,79 1.62–12.50 0.018
Neoadjuvant treatment
No 86 1 1
Yes 37 7.67 2.03–29.00 0.001 1.60 0.29–8.87 0.593
Immunohistochemistry
EGFR
Low to moderate (0–1–2) 87 1 1
High (3) 54 2.10 1.18–4.53 0.038 1.31 0.60–2.83 0.499
KIT
Negative (0) 76 1 1
Positive (3) 0 2.38 1.44–3.94 0.001 2.36 0.67–6.42 0.109
IGF-1R
Low (1) 96 1 1
Moderate to high (2–3) 43 13.11 1.68–26.62 0.001 3.07 0.38–24.59 0.291
CI, confidence interval.
Girard et al. Journal of Thoracic Oncology • Volume 5, Number 9, September 2010
Copyright © 2010 by the International Association for the Study of Lung Cancer1444
tion but minimally affected ERK signaling.10,25 In vitro stud-
ies showed that IGF-1R activation participates in the resis-
tance to EGFR inhibitors gefitinib and erlotinib through
formation of EGFR/IGF-1R heterodimers, continued activa-
tion of the PI3K-AKT pathway, and inhibition of the pro-
apoptotic protein survivin.20,22,26 Conversely, EGFR activa-
tion may modulate the sensitivity of cells to IGF-1R
inhibitors, as suggested in neuroblastoma and sarcoma in
vitro models.27 The existence of such mechanisms remains to
be investigated in thymic malignancies. A potential difficulty
is the absence of available cell lines and animal models for
these tumors.
In our series, IGF-1R expression level was not a sig-
nificant prognostic variable on time to progression at multi-
variate analysis (HR  3.07; 95% CI: 0.38–24.59; p 
0.291). Only tumor stage (HR  4.12; 95% CI: 1.98–14.23;
p  0.010) and histologic type (thymic carcinoma versus
thymoma; HR  2.79; 95% CI: 1.62–12.50; p  0.018) were
significant prognostic factors. This finding is consistent with
previous data from larger cohort of patients with thymic
tumors.2,27,28 To our knowledge, no study has investigated the
prognostic value of tumor tissue biomarkers in thymic ma-
lignancies so far. Such studies would require long-term fol-
low-up given the high frequency of late recurrences occurring
more than 5 years after initial treatment and the prolonged
survival of patients.3,28 The absence of significant influence
of IGF-1R expression levels on time to progression in this
study may be related to a lack of power given the relatively
low number of events even after a median follow-up of 61
months.
Moreover, conflicting data about the prognostic value
of IGF-1R expression have been reported in human cancers.
In NSCLC, four large studies were performed, collectively
including more than 750 tumor specimens and correlating
patient outcome with IGF-1R expression levels at immuno-
histochemistry.5,10,14,17 These studies consistently failed to
show any significant prognostic value for IGF-1R expression.
In breast cancer, IGF-1R expression has been reported both
as a favorable30,31 and unfavorable prognostic factor.32
IGF-1R expression has been associated with prolonged sur-
vival in esophageal cancer,18 myeloma,33 and soft tissue
sarcoma34 but with a poor outcome in renal and cervical
carcinoma.35,36
Even if not a prognostic factor, IGF-1R expression may
still represent a potent predictive marker of response to
specific IGF-1R inhibitors. This was observed in NSCLC, for
which, as shown earlier, IGF-1R expression does not influ-
ence survival5,10,14,17 but may be associated with better sen-
sitivity to IGF-1R inhibitors. A recent in vitro study recently
showed that the growth of cell lines harboring high-IGF-1R
expression is more readily inhibited after exposure to
R1507.10 In a phase II trial including 180 patients with
advanced NSCLC, the adjunction of figitumumab to standard
cisplatin-based chemotherapy led to significantly higher re-
sponse rates (from 32 to 46%),37 especially in squamous cell
carcinoma tumors (72%) that more frequently express IGF-
1R, as shown earlier. Again, the lack of cell lines and
preclinical models prevented us from analyzing further the
functional consequences of anti-IGF-1R therapy in thymic
malignancies.
Given these correlations in other cancers, our data,
showing the high frequency of IGF-1R expression in thymic
malignancies, then reasonably support further evaluation of
IGF-1R inhibitors at least in thymic tumors with IGF-1R
overexpression. An ongoing phase II trial evaluates IMC-A12
(ImClone Systems Incorporated, Branchburg, NJ), an anti-
IGF-1R antibody, in advanced and refractory thymomas and
thymic carcinomas (clinicaltrials.gov ID: NCT00965250).
To conclude, the identification of IGF-1R expression in
thymic malignancies represents a promising rationale for the
development of targeted therapies against the IGF-1R path-
way in these rare tumors with limited therapeutic options.
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